June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Safety and Efficacy of DE-117, a Selective EP2 Agonist in a Phase 2a Study
Author Affiliations & Notes
  • Nnenna Ihekoromadu
    Global Research and Development, Santen, Emeryville, CA
  • Fenghe Lu
    Global Clinical Science, Santen, Emeryville, CA
  • Ryo Iwamura
    Ube Industries, Ltd, Osaka, Japan
  • Kenji Yoneda
    Ube Industries, Ltd, Osaka, Japan
  • Noriko Kawabata-Odani
    Global Research and Development, Santen, Emeryville, CA
  • Naveed Kamal Shams
    Global Research and Development, Santen, Emeryville, CA
  • Footnotes
    Commercial Relationships Nnenna Ihekoromadu, Santen Pharmaceutical (E); Fenghe Lu, Santen Pharmaceutical (C); Ryo Iwamura, Ube Industries, Ltd (E); Kenji Yoneda, Ube Industries, Ltd (E); Noriko Kawabata-Odani, Santen Pharmaceutical Co.,Ltd (E); Naveed Shams, Santen Pharmaceutical (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5708. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nnenna Ihekoromadu, Fenghe Lu, Ryo Iwamura, Kenji Yoneda, Noriko Kawabata-Odani, Naveed Kamal Shams; Safety and Efficacy of DE-117, a Selective EP2 Agonist in a Phase 2a Study. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5708.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To investigate the safety, efficacy and dose response of 4 concentrations of DE-117 ophthalmic solution (0.0003%, 0.001%, 0.002% and 0.003%) compared to Latanoprost (0.005%, LAT) and placebo (PBO) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)

 
Methods
 

This was a randomized, observer-masked, placebo-and-active-controlled, parallel-group, multi-center study in 91 patients. After a washout period of up to 28 days, a baseline intraocular pressure (IOP) of 22-35 mmHg at 08:00 and at each additional time point was required. The eye with the higher diurnal IOP at baseline was the study eye. Both eyes were treated once daily at 20:00 for 4 weeks. Safety was assessed by adverse events (AEs) reported. Efficacy was assessed by changes in IOP from baseline. IOP was measured at 8:00, 10:00, 12:00 and 16:00 at baseline and weeks 1, 2 and 4 visits.

 
Results
 

All doses of DE-117 were well-tolerated. The AEs of conjunctival hyperaemia, ocular hyperaemia, photophobia and eye pain were reported in the DE-117 groups (0.001%, 0.002% or 0.003%), however they were all mild and transient (Table 1).<br /> DE-117 0.002% showed numerically greater IOP reduction than LAT at Week 1 and similar IOP reduction compared to LAT through Week 4. DE-117 0.002% outperformed the rest of DE-117 groups in IOP reduction. (Figure 1). The lower DE-117 doses demonstrated a typical increasing dose response relationship, while the highest dose (0.003% DE-117) was not as effective as the 0.002% dose.

 
Conclusions
 

DE-117 was safe and well tolerated in patients with POAG and OHT. A U-shaped dose relationship was observed. The 0.003% dose was less effective than the 0.002% DE-117 dose. The 0.002% dose had numerically greater IOP reduction from baseline compared to LAT at Week 1, but similar efficacy to LAT through Week 4.  

 
Table 1: Common AEs (Incidence > 10% in any Group)
 
Table 1: Common AEs (Incidence > 10% in any Group)
 
 
Figure 1: IOP by Visit and Time Point
 
Figure 1: IOP by Visit and Time Point

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×